Endothelial Dysfunction in Diabetes Mellitus

ABSTRACT

Diabetes mellitus and impaired glucose tolerance are linked to increased cardiovascular morbidity and mortality. Vascular disease is directly associated with plasma glucose levels, and reduction of these levels forestalls to a certain extent the vascular complications of diabetes, such as myocardial infarction, nephropathies, and retinopathies. In addition to hyperglycemia, there are other risk factors that play a prominent role, such as hypertension, hyperlipidemia, and genetic factors. Endothelial dysfunction is one of the major factors in the development of cardiovascular disease. The vascular endothelium regulates the blood flow by tightly controlling the coagulation system, cell-cell interaction, and vascular tone. These functions are disturbed in diabetic patients. In diabetics, endothelin-1 levels are increased, leading to vasoconstriction. Endothelin levels are directly related to plasma glucose levels. In addition, the endothelial cell-NO axis is disturbed. NO release and function are impaired. This seems to be dependent upon hyperglycemia and genetic factors. Impaired NO function also results in vasoconstriction. Furthermore, enhanced vascular permeability is seen in diabetics. This appears to be related to impaired endothelial cell relaxation and reactive oxygen species as well as advanced glycosylated end products (AGEs). The complex changes seen in diabetes and even prediabetes are therefore related to numerous derailments related to endothelial dysfunction, and no single therapeutic approach is likely to solve the problem of vascular complications.

KEYWORD

Diabetes - endothelium - hyperglycemia - vascular permeability - cardiovascular disease

REFERENCES

• 1 Eriksson K F, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise.  Diabetologia . 1998;  41 1010-1016
• 2 Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia . 1985;  28 22-27
• 3 Eriksson J, Lindström J, Valle T. Prevention of type II diabetes in subjects with impaired glucose tolerance: The diabetes prevention study (DPS) in Finland.  Diabetologia . 1999;  40 793-801
• 4 Tominaga M, Eguchi H, Manaka H. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose.  Diabetes Care . 1999;  22 920-924
• 5 Kurtschiev T, Koehler C, Schaper F. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.  Diabetologia . 1998;  41 706-712
• 6 Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes.  Diabetes . 1999;  48 937-942
• 7 Valensi P, Giroux C, Ghalayini B, Attali J R. Diabetic peripheral neuropathy: Effects of age duration of diabetes, glycemic control, and vascular factors.  J Diabetes Complications . 1997;  11 27-34
• 8 Schmidt M I, Duncan B B, Sharrett A R. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): A cohort study.  Lancet . 1999;  353 1649-1652
• 9 Wu J T. Review of diabetes: Identification of markers for early detection, glycemic control, and monitoring clinical complications.  J Clin Lab Anal . 1993;  7 293-300
• 10 Winkler G, Lakatos P, Salamon F. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients.  Diabetic Med . 1999;  16 207-211
• 11 Koch M, Rett K, Volk A. The tumor necrosis factor alpha- 238 G → A and -308 G → A promoter polymorphisms are not associated with insulin sensitivity and insulin secretion in young healthy relatives of type II diabetic patients.  Diabetologia . 2000;  43 181-184
• 12 UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet . 1998;  352 837-853
• 13 DCCT: Diabetes Control and Complications Trial. The absence of a glycemic threshold for the development of long-term complications: The perspective of the Diabetes Control and Complications Trial.  Diabetes . 1996;  45 1289-1298
• 14 Gu K, Cowie C, Harris M. Diabetes and decline in heart disease mortality in US adults.  JAMA . 1999;  281 1291-1297
• 15 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction.  N Engl J Med . 1999;  341 217-225
• 16 Haffner S M, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med . 1998;  339 229-234
• 17 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study.  Lancet . 1999;  353 617-622
• 18 Baron A D. Vascular reactivity.  Am J Cardiol . 1999;  84 25-27
• 19 Simon B C, Noll B, Maisch B. Endothelial dysfunction: Update and clinical implications.  Herz . 1999;  24 62-71
• 20 Stern D M, Esposito C, Gerlach H. Endothelium and regulation of coagulation.  Diabetes Care . 1991;  14 160-166
• 21 Rao K, Chouhan V, Chen X, Sun L, Boden G. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men.  Diabetes . 1999;  48 1156-1161
• 22 Fenner E, King G L. Vascular dysfunction in diabetes mellitus.  Lancet . 1997;  350(Suppl I) 9-13
• 23 Neri S, Bruno C M, Leotta C. Early endothelial alterations in non-insulin-dependent diabetes mellitus.  Int J Clin Lab Res . 1998;  28 100-103
• 24 Stehouwer C DA, Lambert J, Donker A JM, van Hinsbergh W M V. Endothelial dysfunction and pathogenesis of diabetic angiopathy.  Cardiovasc Res . 1997;  34 55-68
• 25 Vehkavaara S, Seppala-Lindroos A, Westerbacka J. In vivo endothelial dysfunction characterizes patients with impaired fasting glucose.  Diabetes Care . 1999;  22 2055-2060
• 26 Miyauchi T, Tomobe Y, Shiba R. Involvement of endothelin in the regulation of human vascular tonus. Potent vasoconstrictor effect and existence in endothelial cells.  Circulation . 1990;  81 1874-1880
• 27 Lerman A, Edwards B S, Hallett J W. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.  N Engl J Med . 1991;  325 997-1001
• 28 Quehenberger P, Bierhaus A, Fasching P. Endothelin-1 transcription is under control of nuclear factor-κB in age-stimulated cultured endothelial cells.  Submitted.
• 29 Takahashi K, Ghatei M A, Lam H C, O`Halloran D J, Bloom S R. Elevated plasma endothelin in patients with diabetes mellitus.  Diabetologia . 1990;  33 306-310
• 30 Hopfner R L, Gopalakrishnan V. Endothelin: Emerging role in diabetic vascular complications.  Diabetologia . 1999;  42 1383-1394
• 31 Khan M A, Dashwood M R, Mumtaz F H. Upregulation of endothelin at receptor sites in the rabbit diabetic kidney: Potential relevance to the early pathogenesis of diabetic nephropathy.  Nephron . 1999;  83 261-267
• 32 Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus.  Diabetes Metab Rev . 1998;  14 171-175
• 33 Winkles J A, Alberts G F, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries.  Biophys Res Commun . 1993;  191 1081-1088
• 34 Zeiher A M, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina.  Circulation . 1995;  91 941-947
• 35 Zeiher A M, Ihling C, Pistorius K, Schachinger V, Schaefer H E. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes.  Lancet . 1994;  344 1405-1406
• 36 Bruzzi I, Benigni A. Endothelin is a key modulator of progressive renal injury: Experimental data and novel therapeutic strategies.  Clin Exp Pharmacol Physiol . 1996;  23 349-353
• 37 DeMattia G, CassoneFaldetta M, Bellini C. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy.  Am J Hypertens . 1998;  11(Part 1) 983-988
• 38 Kohan D E. Endothelins in the normal and diseased kidney.  Am J Kidney Dis . 1997;  29 2-26
• 39 Benigni A, Colosio V, Brena C. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.  Diabetes . 1998;  47 450-456
• 40 Furchgott R F, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.  Nature . 1980;  288 373-376
• 41 Palmer R M, Ferrige A G, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.  Nature . 1987;  327 524-526
• 42 Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.  J Clin Invest . 1991;  87 432-438
• 43 Hunt J V, Smith C CT, Wolff S P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modifications.  Diabetes . 1990;  39 1420-1424
• 44 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biological and clinical implications for diabetes and aging.  Lab Invest . 1994;  70 138-151
• 45 Basta G, De Caterina R. Products of advanced glycosylation and the pathogenesis of accelerated atherosclerosis in diabetes.  G Ital Cardiol . 1996;  26 699-719
• 46 Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications.  Diabetes Care . 1996;  19 257-267
• 47 Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension and cardiovascular disease: Which role for oxidative stress?.  Metabolism . 1995;  44 363-368
• 48 McCarty M F. Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium: A key role for selenium-dependent enzymes in vascular health.  Med Hypothesis . 1999;  53 315-325
• 49 Malek A M, Alper S L, Izumo S. Hemodynamic shear stress and its role in atherosclerosis.  JAMA . 1999;  282 2035-2042
• 50 Celermajer D S, Sorensen K E, Gooch V M. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet . 1992;  340 1111-1115
• 51 Joannides R, Haefeli W, Linder L. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo.  Circulation . 1995;  91 1314-1319
• 52 Sorensen K E, Celermajer D S, Spiegelthaler D J. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility.  Br Heart J . 1995;  74 247-253
• 53 Balletshofer B M, Rittig K, Enderle M D. Endothelial dysfunction is detectable in young normotensive first degree relatives of subjects with type 2 diabetes in association to insulin resistance.  Circulation . 2000;  101 1780-1784
• 54 Enderle M D, Benda N, Schmuelling R M. Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects.  Diabetes Care . 1998;  21 271-277
• 55 King G L, Brownlee M. The cellular and molecular mechanisms of diabetic complications.  Endocrinol Metab . 1996;  25 255-270
• 56 Akbari C M, Saouaf R, Barnhill D F. Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia.  J Vasc Surg . 1998;  28 687-694
• 57 Kawano H, Motoyama T, Hirashima O. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.  J Am Coll Cardiol . 1999;  34 146-154
• 58 Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system.  Haemostasis . 1993;  23(Suppl I) 118-126
• 59 Galle J, Heermeier K. Angiotensin II and oxidized LDL: An unholy alliance creating oxidative stress.  Nephrol Dial Transplant . 1999;  14 2585-2589
• 60 Pueyo M, Michel J B. Effect of angiotensin II on vascular remodeling.  Nephrologie . 1998;  19 443-449
• 61 Touyz R M, Schiffrin E L. Angiotensin II stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells.  Hypertension . 1999;  34(Part 2 Suppl S) 976-982
• 62 Remme W J. Effect of ACE inhibition on neurohormones.  Eur Heart J . 1998;  19(Suppl J) J16-J23
• 63 Mullen M J, Clarkson P, Donald A E. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: A randomized, double-blind study.  J Am Coll Cardiol . 1998;  31 1330-1335
• 64 Mäkimattila S, Virkamäki A, Groop P H. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus.  Circulation . 1996;  94 1276-1282
• 65 Makita Z, Yanagisawa K, Kuwajima S. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis.  Nephrol Dial Transplant . 1996;  11(Suppl 5) 31-33
• 66 Mougenot N, Lesnik P, Ramirez-Gil J F. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro.  Atherosclerosis . 1997;  133 183-192
• 67 Posch K, Simecek S, Wascher T C. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells.  Diabetes . 1999;  48 1331-1337
• 68 Koenig W. Atherosclerosis involves more than just lipids: Focus on inflammation.  Eur Heart J Suppl . 1999;  1 T19-T26
• 69 Weissberg P L. Atherosclerosis involves more than just lipids: Plaque dynamics.  Eur Heart J Suppl . 1999;  1 T13-T18
• 70 Sheu W H, Juang B L, Chen Y T, Lee W J. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia.  Diabetes Care . 1999;  22 1224-1225
• 71 Cosentino F, Luscher T F. Endothelial dysfunction in diabetes mellitus.  J Cardiovasc Pharmacol . 1998;  32(Suppl 3) S54-S61
• 72 Pfister M, Seiler C, Fleisch M. Nitrate induced coronary vasodilatation: Differential effects of sublingual application by capsule or spray.  Heart . 1998;  80 365-369
• 73 Cameron N E, Cotter M A. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.  Diabetes Res Clin Pract . 1999;  45 137-146
• 74 Nakayama M, Izumi G, Nemoto Y. Suppression of N-epsilon-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine.  Peritoneal Dial Int . 1999;  19 207-210
• 75 Munzel T, Heitzer T, Harrison D G. The physiology and pathophysiology of the nitric oxide/superoxide system.  Herz . 1997;  22 157-172
• 76 Beverelli F, Bea M L, Puybasset L, Giudicelli J F, Berdeaux A. Chronic inhibition of NO synthase enhances the production of prostacyclin in coronary arteries through upregulation of the cyclooxygenase type 1 isoform.  Fundam Clin Pharmacol . 1997;  11 252-259
• 77 Kawagishi T, Matsuyoshi M, Emoto M. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes.  Arterioscler Thromb Vasc Biol . 1999;  19 2509-2516
• 78 Wautier J L, Zoukourian C, Chappey O. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rat.  J Clin Invest . 1996;  97 238-243
• 79 Osicka T M, Yu Y X, Panagiotopoulos S. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.  Diabetes . 2000;  49 87-93
• 80 Soulis T, Cooper M E, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment.  Kidney Int . 1996;  50 627-634
• 81 He C J, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.  Diabetes . 1999;  48 1308-1315
• 82 Luscher T F, Noll G. Endothelium dysfunction in the coronary circulation.  J Cardiovasc Pharmacol . 1994;  24(Suppl 3) S16-S26
• 83 Han R O, Ettenson D S, Koo E WY. Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells.  Am J Physiology . 1997;  42 H2586-H2595
• 84 Elliot S J, Striker L J, Stetler-Stevenson W G, Jacot T A, Striker G E. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells.  J Am Soc Nephrol . 1999;  10 62-68
• 85 Verrotti A, Catino M, Di-Ricco L, Casani A, Chiarelli F. Prevention of microvascular complications in diabetic children and adolescents.  Acta Paediatr . 1999;  88(Suppl 427) 35-38
• 86 Mogensen C E. Preventing end-stage renal disease.  Diabetic Med . 1998;  15(Suppl 4) S51-S56
• 87 Barnes P J, Karin M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases.  N Engl J Med . 1997;  336 1066-1071
• 88 Kislinger T, Fu C F, Huber B. N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.  J Biol Chem . 1999;  274 31740-31749
• 89 Borcea V, Morcos M, Isermann B. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.  Vasa . 1999;  28 172-180
• 90 Kessler L, Wiesel M L, Attali P. Von Willebrand factor in diabetic angiopathy.  Diabetes Metab . 1998;  24 327-336
• 91 Valensi P, Pariès J, Zkhiri F. Effects of gamma linolenic acid supplementation on rheological properties of erythrocytes in type 2 diabetic patients with peripheral polyneuropathy.  J Mal Vasc . 1996;  21 185-187
• 92 Bursell S E, Clermont A, Aiello L P. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes.  Diabetes Care . 1999;  22 1245-1251
• 93 Seljeflot I, Arnesen H, Brude I R. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers.  Eur J Clin Invest . 1998;  28 629-635
• 94 Jain S K. Should high-dose vitamin E supplementation be recommended to diabetic patients?.  Diabetes Care . 1999;  22 1242-1244
• 95 Celermajer D S, Adams M R, Clarkson P. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults.  N Engl J Med . 1996;  334 150-154
• 96 Zhan J, Ying X, Lu Q. A single high dose of vitamin C counteracts the acute negative effect on microcirculation induced by smoking a cigarette.  Mikrovasc Res . 1999;  58 305-311
• 97 Poredos P, Orehek M, Tratnik E. Smoking is associated with dose-related increase of intima-media thickness and endothelial dysfunction.  Angiology . 1999;  50 201-208
• 98 Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients.  Mol Med . 1999;  5 393-405
• 99 Schleicher E D, Wagner E, Nerlich A G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging.  J Clin Invest . 1997;  99 457-468